Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 415-423

  Hehlmann, Rüdiger ^a   Müller, Martin C ^a   Lauseker, Michael ^c   Hanfstein, Benjamin ^a   Fabarius, Alice ^a   Schreiber, Annette ^a   Proetel, Ulrike ^a   Pletsch, Nadine ^a   Pfirrmann, Markus ^c   Haferlach, Claudia ^g   Schnittger, Susanne ^g   Einsele, Hermann ^h   Dengler, Jolanta ^b   Falge, Christiane ⁱ   Kanz, Lothar ^j   Neubauer, Andreas ^k   Kneba, Michael ^l   Stegelmann, Frank ^m   Pfreundschuh, Michael ⁿ   Waller, Cornelius F ^o   Spiekermann, Karsten ^f   Baerlocher, Gabriela M ^t   Ehninger, Gerhard ^p   Heim, Dominik ^u   Heimpel, Hermann ^m   Nerl, Christoph ^d   Krause, Stefan W ^q   Hossfeld, Dieter K ^r   Kolb, Hans Jochem ^e   Hasford, Joerg ^c   Saußele, Susanne ^a   Hochhaus, Andreas ^s   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Klinikum Schwabing   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL MARBURG   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^q UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^r UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^s JENA UNIVERSITY HOSPITAL   (Germany)

^t UNIVERSITY OF BERN   (Switzerland)

^u UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; BCR ABL1 FUSION PROTEIN, HUMAN; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERNATIONAL SCALE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REMISSION; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CYTARABINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897574239     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.9020     Document Type: Article

References (35)

1. Gambacorti-Passerini C, Antolini L, Mahon FX, et al: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553-561, 2011
2. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
3. Ross DM, Branford S, Seymour JF, et al: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 122:515-522, 2013
4. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003 (Pubitemid 37211057)
5. Branford S, Yeung DT, Ross DM, et al: Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818-3824, 2013
6. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al: Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634-1642, 2011
7. Fabarius A, Leitner A, Hochhaus A, et al: Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood 118:6760-6768, 2011
8. Hanfstein B, Müller MC, Hehlmann R, et al: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096-2102, 2012
9. Saussele S, Lauseker M, Gratwohl A, et al: Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115:1880-1885, 2010
10. Hanfstein B, Müller MC, Kreil S, et al: Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96:360-366, 2011
11. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006 (Pubitemid 44394987)
12. Baccarani M, Cortes J, Pane F, et al: Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041-6051, 2009
13. Hasford J, Baccarani M, Hoffmann V, et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 118:686-692, 2011
14. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006 (Pubitemid 43990609)
15. Cross NC, White HE, Müller MC, et al: Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172-2175, 2012
16. Müller MC, Cross NC, Erben P, et al: Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957-1963, 2009
17. Branford S, Fletcher L, Cross NC, et al: Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112:3330-3338, 2008
18. Pfirrmann M, Hochhaus A, Lauseker M, et al: Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 25:1433-1438, 2011
19. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
20. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983 (Pubitemid 14202071)
21. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26:2389-2430, 2007 (Pubitemid 46730255)
22. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765, 2010
23. Hehlmann R: How I treat CML blast crisis. Blood 120:737-747, 2012
24. Baccarani M, Deininger MW, Rosti G, et al: European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872-884, 2013
25. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
26. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010
27. Cortes JE, Baccarani M, Guilhot F, et al: Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424-430, 2010
28. Baccarani M, Rosti G, Castagnetti F, et al: Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: A European LeukemiaNet study. Blood 113:4497-4504, 2009
29. Kantarjian H, Talpaz M, O'Brien S, et al: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004 (Pubitemid 38451654)
30. Cortes JE, Kantarjian HM, Goldberg SL, et al: High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754-4759, 2009
31. Castagnetti F, Palandri F, Amabile M, et al: Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party. Blood 113:3428-3434, 2009
32. Hughes TP, Branford S, White DL, et al: Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112:3965-3973, 2008
33. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
34. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
35. Talpaz M, Hehlmann R, Quintás-Cardama A, et al: Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 27:803-812, 2013